Skip to content

Institute of Integrative BioOncology

Omega Precision Oncology

Book a Consultation

ONCOSCOPE · PERSPECTIVE AND UNDERSTANDING

The Best Diets for Cancer Survivors

“One cannot think well, love well, sleep well, if one has not dined well.” – Virginia Woolf, A Room of One’s Own Over the years, many studies have been conducted that suggest following certain healthy diets can help prevent up to 50% of all cancers. These studies have shown that our dietary habits have some impact on increasing or decreasing the risk of cancer. Not only can the science of nutrition help decrease the risk of developing cancer, but it can also help those who are already being treated for cancer. In this article, I will cover which healthy foods and diets are the best for preventing and coping with cancer.

Published

OncoScope provides educational information. It does not replace advice from your treating physician.

Continue exploring.

Article

Drugs as Expanding Cancer Treatment Palette: Albendazole

Drug repurposing is quickly becoming one of the most popular trends in healthcare today. Aside from cutting research and development costs considerably, these “old drugs” are safe and efficient. One of these drugs is albendazole. Albendazole’s primary use is for treating neurocysticercosis, a disease in the nervous system caused by pork tapeworms. In addition, it is also effective in treating cystic hydatid disease in the peritoneum, lungs, and liver. It is highly effective in eliminating dog tapeworm, which causes the infection. Recently, doctors discovered albendazole’s potential in treating cancer. It contains anti-cancer properties that are potentially effective in treating terminal cancer cases. This blog post will highlight albendazole’s mode of action, side effects, and benefits. So, if you’re ready to learn more interesting facts about this drug, let’s start our discussion below.

Drug Repurposing and Off-label Use · Supplements and Phytochemicals

Tags: Drug Repurposing

Read more about Drugs as Expanding Cancer Treatment Palette: Albendazole

Article

Low-Dose Hypomethylating Agents for Myelodysplastic Syndromes (MDS)

Low-dose hypomethylating agents offer promising, well-tolerated disease control for low-risk myelodysplastic syndromes. Recent trials show decitabine achieves a 67% response rate versus 48% for azacitidine, frequently restoring transfusion independence. With a median overall survival of 33 months, low-dose therapy presents a valuable alternative for low-intermediate risk patients.

Cancer · Cancer Biology · Drug Repurposing and Off-label Use

Tags: HMA Treatmentmds

Read more about Low-Dose Hypomethylating Agents for Myelodysplastic Syndromes (MDS)

YOU DO NOT HAVE TO HAVE EVERY ANSWER

Let’s take the next step together.

A thoughtful conversation can help you understand your options and prepare for what comes next.

Request a Consultation